Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA ( (FR:IPH) ) has issued an announcement.
Innate Pharma S.A., a clinical-stage oncology biotechnology company focused on immunotherapies and next-generation antibody therapeutics, is advancing a diversified pipeline targeting high unmet medical needs in solid tumors and hematologic malignancies. Its key assets include IPH4502, a Nectin-4 antibody-drug conjugate, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab for non-small cell lung cancer, developed with AstraZeneca.
On April 8, 2026, Innate Pharma announced that Chief Operating Officer Yannis Morel will present the company’s oncology pipeline and strategy at the AACR Oncology Industry Partnering Event in San Diego on April 16, 2026. Participation in this investor- and industry-focused forum underscores external recognition of Innate’s clinical pipeline and offers a strategic opportunity to showcase its programs, potentially strengthening industry partnerships and visibility among analysts and investors.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.00 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company specializing in cancer immunotherapies. Leveraging antibody engineering and innovative target identification, it is developing next-generation antibody therapeutics, including potential first- or best-in-class assets such as IPH4502 for solid tumors, lacutamab for T cell lymphomas, and monalizumab for NSCLC in collaboration with AstraZeneca.
The company focuses on areas of high unmet medical need and advances its pipeline through partnerships with major biopharmaceuticals like Sanofi and AstraZeneca, as well as leading academic institutions. Headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma is dual-listed on Euronext Paris and Nasdaq under the tickers IPH and IPHA, respectively.
Average Trading Volume: 189,211
Technical Sentiment Signal: Sell
Current Market Cap: €103.5M
For an in-depth examination of IPH stock, go to TipRanks’ Overview page.